Skip to main content
Erschienen in: Familial Cancer 3/2018

15.09.2017 | Letter to the Editor

Germline mutations in lung cancer and personalized medicine

verfasst von: Francesco Cetta, Alessandra Renieri, Elisa Frullanti

Erschienen in: Familial Cancer | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Excerpt

Marafie et al. [1] identified a rare germline NBN gene mutation by whole exome sequencing (WES) in a lung cancer survivor from a large family with various types of cancer. Actually, they found 3 siblings, who had lung cancer at age 55, 54 and 49, respectively. The proband, a 59 year-old heavy cigarette smoker female, was diagnosed with lung cancer at age 49, and her histopathologic report revealed an adenocarcinoma (ADCA) of the middle lobe. At genetic analysis, the proband was found to be a heterozygous carrier for a rare variant in NBN gene, termed c.93_94delTG, a two bases-deletion disrupting the protein function and considered pathogenic. Moreover, the proband had other variants in RAD50 and BRCA1 genes, which are currently considered of uncertain clinical significance. Among the 8 tested subjects, including a yet asymptomatic sister, 6 carried one or more of these variants in different combinations and in an heterozygous state. NBN (nibrin) encodes a member of the MRE11/RAD50 double-strand break repair complex, which is an integral component of the BRCA1-associated genome surveillance complex, responsible for double strand DNA damage repair. Heterozygous carriers of NBN 657del5 mutation showed an increased risk of developing various tumors. …
Literatur
1.
Zurück zum Zitat Marafie MJ, Dashti M, Al-Mulla F (2017) Identification of a rare NBN gene mutation by whole exam sequencing in a lung cancer survivor from a large family with various types of cancer. Fam Cancer 16:389–394CrossRefPubMed Marafie MJ, Dashti M, Al-Mulla F (2017) Identification of a rare NBN gene mutation by whole exam sequencing in a lung cancer survivor from a large family with various types of cancer. Fam Cancer 16:389–394CrossRefPubMed
2.
Zurück zum Zitat Renieri A, Mencarelli MA, Cetta F et al (2014) Oligogenic germline mutations identified in early non smokers lung adenocarcinoma patients. Lung Cancer 85(2):168–174CrossRefPubMed Renieri A, Mencarelli MA, Cetta F et al (2014) Oligogenic germline mutations identified in early non smokers lung adenocarcinoma patients. Lung Cancer 85(2):168–174CrossRefPubMed
3.
Zurück zum Zitat Baldassari M, Fallerini C, Cetta F et al (2017) “Omic” approach in non-smokier female with lung squamous cell carcinoma pinpoints to gremlin susceptibility and personalized medicine. Cancer Res Treat. doi:10.4143/crt.2017.125 [Epub ahead of print] CrossRef Baldassari M, Fallerini C, Cetta F et al (2017) “Omic” approach in non-smokier female with lung squamous cell carcinoma pinpoints to gremlin susceptibility and personalized medicine. Cancer Res Treat. doi:10.​4143/​crt.​2017.​125 [Epub ahead of print] CrossRef
5.
Zurück zum Zitat Cetta F (2015) FAP associated papillary thyroid carcinoma: a peculiar subtype of familial non medullary thyroid cancer. Patholog Res Int. 2015:309348PubMedPubMedCentral Cetta F (2015) FAP associated papillary thyroid carcinoma: a peculiar subtype of familial non medullary thyroid cancer. Patholog Res Int. 2015:309348PubMedPubMedCentral
Metadaten
Titel
Germline mutations in lung cancer and personalized medicine
verfasst von
Francesco Cetta
Alessandra Renieri
Elisa Frullanti
Publikationsdatum
15.09.2017
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2018
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0044-4

Weitere Artikel der Ausgabe 3/2018

Familial Cancer 3/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.